Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2018-08-01 Director's Dealing
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-08-01 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Novavax, Inc. It registers additional shares under employee stock plans. Form S-8 is a registration statement used for securities issued under employee benefit plans. The document includes details about the stock plans, indemnification provisions, and references to other filings but does not contain financial statements or earnings data. It is not an annual report, earnings release, or any other financial report type. It is a capital/financing related filing concerning registration of securities for employee plans. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains the full registration statement, not just an announcement, so it is not RPA or RNS.
2018-08-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a Second Amended and Restated Joint Venture Agreement) between Novavax, Inc. and Cadila Pharmaceuticals Ltd. It details the nature of the agreement and states that the full agreements will be filed later as exhibits to a Form 10-Q. There are no financial statements or detailed financial analysis present, only a description of the agreement and a reference to future filings. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like M&A Activity or Capital/Financing Update since it is about a joint venture agreement amendment without explicit merger or financing terms. The document length is about 4,832 characters, which is consistent with a typical 8-K filing. Therefore, the best classification is Regulatory Filings (RNS).
2018-07-24 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 14, 2018, for Novavax, Inc. The content focuses on the submission of matters to a vote of security holders at the Annual Meeting of Stockholders, including election of directors, approval of executive compensation, stock incentive plans, employee stock purchase plans, and ratification of the independent auditor. This corresponds to official results from shareholder votes at a general meeting. The document is not a full annual report, earnings release, or management discussion, but specifically reports voting results. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains detailed voting results, confirming it is not merely an announcement of a report but the actual voting results.
2018-06-15 English
Regulatory Filings 2018
Regulatory Filings
2018-06-08 English
FORM 4 SUBMISSION
Director's Dealing
2018-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.